On December 12, Gelonghui Medical (301060.SZ) stated on the investor interactive platform on December 12 that the company has sufficient testing capabilities and technical reserves for mycoplasma pneumoniae and drug resistance genetic testing to meet customer needs.
兰卫医学(301060.SZ)：公司对肺炎支原体及耐药基因检测具备足够的检测能力和技术储备
Lanwei Medicine (301060.SZ): The company has sufficient testing capabilities and technical reserves for mycoplasma pneumoniae and drug resistance genetic testing
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.